About Ocular Genomics

Both gene expression and the presence of specific gene sequences can be used as biomarkers for many diseases, including eye diseases. Ophthalmic genomic discoveries will expand our understanding of ocular diseases/traits by identifying associated genetic variants, genes, and pathways. This could lead to early detection and effective treatment of many ocular diseases that can lead to blindness. Researchers study inherited eye diseases primarily by analyzing the coding exons of genes (genome, clinical exome), including undetected variants in related genes (intron, upstream/downstream, structural variants), variants in genes outside the target group, intergenic variants, variants undetectable by applying existing techniques, complex/non-Mendelian inheritance and non-genetic phenotypes. These studies can be help researchers develop appropriate therapeutic drugs faster.

Fig. 1. Sample collection, DNA isolation and shotgun metagenomic sequencing. (Kirstahler P, et al., 2018)

Our Services

As a comprehensive ophthalmic solutions company, Ace Therapeutics' scientists conduct large-scale gene expression studies to identify genes that are up- or down-regulated in specific indications or diseases. Our bioanalytical team has extensive experience in the development and validation of biomarker assays. This relies on the ability of our researchers to design exploratory and confirmatory panels. Moreover, they have powerful software tools to analyze the resulting data and identify underlying ocular genome biomarkers.

At Ace Therapeutics, we will accelerate drug development by incorporating genomics into biomarker discovery and analysis workflows. Methods such as RNASeq, PCR, and next-generation sequencing (NGS) provide detailed genomic and transcriptomic insights into the complexity of ophthalmic diseases and novel biomarkers such as gene mutations and changes in gene expression in eye cancer. These assays are suitable for high-throughput methods in large-scale preclinical studies requiring parallel assessment of a large number of genomic biomarkers.

Ace Therapeutics' genomic biomarker solutions address key challenges in biomarker discovery and validation!

General Strategy

Scientists at Ace Therapeutics perform a genome-wide association study on eye specimens, in which DNA samples from different species were genetically analyzed using microarrays to obtain a large number of single nucleotide polymorphism (SNP) genomes distributed in various regions, followed by statistical analysis to detect associations of the most common genetic variants. In addition, for rare variants, our genetic experts usually use whole exome sequencing (WES) or even whole genome sequencing (WGS) for detection. Finally, the genotypes of different species and patients were analyzed to discover potential ocular genome biomarkers.

What Can We Provide?

According to the research needs of global customers on ocular genome biomarkers, Ace Therapeutics has developed the following service platforms to accelerate the development of customers' projects, including but not limited to.

• Ocular whole genome sequencing.
• Ocular whole exome sequencing.
• Single cell RNA sequencing.
• Ocular targeted genome sequencing.
• Genome-wide association studies.
• Cytogenetic analysis.
• Epigenetic analysis.
• Gene expression analysis.

Our Advantages

• Rich experience in genomics and biomarker analysis.
• Unique comprehensive service for ocular biomarker research.
• excellent research team.
• Comprehensive research platforms.

Ace Therapeutics has the most experienced team to serve global customers. Our scientists are always ready to provide high-quality genomics-based ocular biomarker discovery and analysis solutions to global customers. If you have questions about the content of this service, please feel free to contact us. We look forward to hearing from you.

Reference

1. Kirstahler P, Bjerrum S S, Friis-Møller A, et al. Genomics-Based Identification of Microorganisms in Human Ocular Body Fluid. Sci Rep. 2018;8(1):4126.

• Proteomic-Based Ocular Biomarker Discovery and Analysis Services
• Metabolomics-Based Ocular Biomarker Discovery and Analysis Services
• Epigenomic-based Ocular Biomarkers Discovery and Analysis Services
• Lipidomics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Cell Biomarker Discovery and Analysis Services
• Ocular Tissue Biomarker Discovery and Analysis Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit